Nanoscope Therapeutics Expands Leadership Team, Appoints Glenn Sblendorio as Chairman of the Board

Nanoscope Therapeutics, a leading clinical-stage biotechnology company specializing in gene therapies for inherited retinal diseases, has appointed Glenn Sblendorio as Chairman of the Board. With over 30 years of distinguished experience, particularly in executive leadership within the ophthalmic industry, Mr. Sblendorio's strategic guidance is poised to play a pivotal role in advancing Nanoscope's mission of providing renewed sight and hope to millions affected by retinal degenerative diseases without current cures.